DE69636085D1 - Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea - Google Patents

Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea

Info

Publication number
DE69636085D1
DE69636085D1 DE69636085T DE69636085T DE69636085D1 DE 69636085 D1 DE69636085 D1 DE 69636085D1 DE 69636085 T DE69636085 T DE 69636085T DE 69636085 T DE69636085 T DE 69636085T DE 69636085 D1 DE69636085 D1 DE 69636085D1
Authority
DE
Germany
Prior art keywords
chorea
huntington
acid
medicament
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636085T
Other languages
English (en)
Other versions
DE69636085T2 (de
Inventor
K S Dr Vaddadi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scarista Ltd
Original Assignee
Scarista Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scarista Ltd filed Critical Scarista Ltd
Application granted granted Critical
Publication of DE69636085D1 publication Critical patent/DE69636085D1/de
Publication of DE69636085T2 publication Critical patent/DE69636085T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
DE69636085T 1995-09-27 1996-09-26 Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea Expired - Lifetime DE69636085T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9519661.4A GB9519661D0 (en) 1995-09-27 1995-09-27 Fatty acid treatment
GB9519661 1995-09-27

Publications (2)

Publication Number Publication Date
DE69636085D1 true DE69636085D1 (de) 2006-06-08
DE69636085T2 DE69636085T2 (de) 2006-12-07

Family

ID=10781324

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636085T Expired - Lifetime DE69636085T2 (de) 1995-09-27 1996-09-26 Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea

Country Status (9)

Country Link
US (1) US5837731A (de)
EP (1) EP0766961B1 (de)
AT (1) ATE324884T1 (de)
AU (1) AU709867B2 (de)
CA (1) CA2186673C (de)
DE (1) DE69636085T2 (de)
ES (1) ES2259442T3 (de)
GB (1) GB9519661D0 (de)
NZ (1) NZ299464A (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199900786T2 (xx) * 1996-10-11 1999-07-21 Scotia Holdings Plc Eykoza penta enoik asit ve/veya stearidonik asit i�eren farmas�tik terkipler.
US6652866B1 (en) * 1997-10-14 2003-11-25 David W. Hertha Method for treating diseases of fungal, yeast, and prion protein etiology
US7138431B1 (en) * 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US7098352B2 (en) * 2001-11-16 2006-08-29 Virtus Nutrition Llc Calcium salt saponification of polyunsaturated oils
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
DE112004001520B4 (de) 2003-08-18 2008-04-10 Btg International Ltd. Verwendung eines Lipidglyzerids festgelegter Struktur zur Herstellung eines Medikamentes zur Behandlung der multiplen Sklerose
EP1765964A4 (de) * 2004-04-30 2007-11-07 Synthese von salzen aus mehrfach ungesättigten fettsäuren und ein- und zweiwertigen metallen
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP3187182B1 (de) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon
BRPI1007518A2 (pt) 2009-02-10 2018-02-20 Amarin Pharma, Inc. uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia
BRPI1011876B1 (pt) 2009-04-29 2020-03-31 Amarin Pharma, Inc. Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular
EP2424521A4 (de) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Pharmazeutische zusammensetzungen mit epa und einem kardiovaskulären mittel sowie verwendungsverfahren dafür
DK2443246T3 (en) * 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ie Ltd COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
CA3147657C (en) * 2010-03-04 2023-03-07 Amarin Pharmaceuticals Ireland Limited Ethyl eicosapentaenoate for maintaining ldl control
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
EP4342546A3 (de) 2012-06-29 2024-05-22 Amarin Pharmaceuticals Ireland Limited Verfahren zur verringerung des risikos von herz-kreislauf-ereignissen bei einem patienten in einer statintherapie
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164291C (en) * 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders

Also Published As

Publication number Publication date
GB9519661D0 (en) 1995-11-29
NZ299464A (en) 2000-12-22
CA2186673A1 (en) 1997-03-28
ES2259442T3 (es) 2006-10-01
EP0766961B1 (de) 2006-05-03
ATE324884T1 (de) 2006-06-15
AU6586896A (en) 1997-04-10
EP0766961A1 (de) 1997-04-09
US5837731A (en) 1998-11-17
AU709867B2 (en) 1999-09-09
DE69636085T2 (de) 2006-12-07
CA2186673C (en) 2008-07-22

Similar Documents

Publication Publication Date Title
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
DE69428268T2 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE231885T1 (de) Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura
ATE267607T1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE234615T1 (de) Verwendung von acetylcystein zur herstellung eines arzneimittels zur behandlung von chronischen geschwüren
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
ATE274349T1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
ATE196738T1 (de) Verwendung von immunglobulin-präparationen zur herstellung eines medikaments zur oralen verabreichung zur behandlung und prophylaxe chronischer schmerzzustände
AU1870097A (en) Use of a medicament and use of mixture of substances to produce a medicament
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
EP0286802A3 (de) Verwendung von Ofloxacin zur lokalen Behandlung oder Prophylaxe von Beschwerden der Wurzelhaut der Zähne
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69428797T2 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition